Emerging drugs for the treatment of pancreatic cancer

Bibliography

• LI D, XIE K, WOLFF R et al. Pancreatic cancer. Lancet(2004) 363:1049-1057.
   PubMed Web of Science ®Google Scholar
• PARKIN DM, BRAY FI, DEVESA SS et al. Cancer burden in the year 2000. The global picture. Eur. J. Cancer (2001) 37:S4-S66.
   PubMed Web of Science ®Google Scholar
• BURRIS H, MOORE MJ, ANDERSEN J et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. J. Clin. Oncol. (1997) 15:2403-2413.
   PubMed Web of Science ®Google Scholar
• HEINEMANN V: Gemcitabine: progress in the treatment of pancreatic cancer. Oncology (2001) 60:8-18.
   PubMed Web of Science ®Google Scholar
• GLIMELIUS B, HOFFMAN K, SJODEN PO et al.: Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann. Oncol. (1996) 7:593-600.
   PubMed Web of Science ®Google Scholar
• LOUVET C, LABIANCA R, HAMMEL P et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer; results of a GERCOR and GISCAD Phase III trial. J. Clin. Oncol. (2005) 23:3509-3516.
   PubMed Web of Science ®Google Scholar
• ABOU-ALFA GK, LETOURNEAU R, HARKER G et al.: Randomized Phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J. Clin. Oncol. (2006) 24:4441-4447.
   PubMed Web of Science ®Google Scholar
• ROCHA-LIMA CM, SAVARESE D, BRUCHNER H et al.: Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J. Clin. Oncol. (2004) 18:3776-3783.
   Google Scholar
• OETTLE H, RICHARDS DL, RAMANATHAN RK et al.: A Phase III trial of permetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann. Oncol. (2005) 16:1639-1645.
   PubMed Web of Science ®Google Scholar
• HEINEMANN V, QUIETZSCH D, GIESELER F et al.: Randomized Phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J. Clin. Oncol. (2006) 24:3946-3952.
   PubMed Web of Science ®Google Scholar
• BERLIN JD, CATALANO P, THOMAS JP et al.: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J. Clin. Oncol. (2002) 20(15):3270-3275.
   PubMed Web of Science ®Google Scholar
• HERRMANN R, BODOKY G, RUHSTALLER B et al.: Gemcitabine plus capecitabine versus gemcitabine alone in locally advanced or metastatic pancreatic cancer: a randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG). Proc. ASCO J. Clin. Oncol. (2005) 2:Abstract 4010.
   Google Scholar
• CUNNINGHAM D, CHAN I, STOCKEN D et al.: Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. Eur. J. Cancer (2005) (Suppl. 3):Abstract PS11.
   Google Scholar
• POPLIN E, LEVY DE, BERLIN J et al. Phase III trial of gemcitabine(30 minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatine (GEMOX) in patients with APC (E 6201); Proc. ASCO J. Clin. Oncol. (2006) 24:185 (Suppl. 1): Abstract 4004.
   Google Scholar
• TEMPERO M, PLUNKETT W, RUIZ VAN HAPERIN V et al.: Randomized Phase II comparison of dose-intense gemcitabine; thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J. Clin. Oncol. (2003) 21:3402-3408.
   PubMed Web of Science ®Google Scholar
• OETTLE H, POST P, NEUHAUS P et al.: Adjuvant chemotherapy with gemcitabine versus observation in patients undergoing curative-intent resection of pancreatic cancer. JAMA (2007) 297:267-277.
   PubMed Web of Science ®Google Scholar
• CRANE CH, WOLFF RA, ABRUZZEZE JL et al.: Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index. Semin. Oncol. (2001) 28:25-33.
   PubMed Web of Science ®Google Scholar
• MORIZANE C, OKUSAKA T, FURUSE J et al.: A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Proc. ASCO J. Clin. Oncol. (2006) 24(Part I):185 Abstract 4115.
   Google Scholar
• YAMANAKA Y, FRIESS H, KOBRIN MS et al.: Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res. (1993) 13:565-569.
   PubMed Web of Science ®Google Scholar
• OVERHOLSER JP, PREWETT MC, HOOPER AT et al.: Epidermal growth factor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer (2000) 89:74-82.
   PubMed Web of Science ®Google Scholar
• HUANG ZQ, BUCHSMAUM DJ, RAISCH KP et al.: Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody. J. Surg. Res. (2003) 111:274-283.
   PubMed Web of Science ®Google Scholar
• XIONG HQ, ROSENBERG A, LOBUGLIO A et al.: Cetuximab, a monocloncal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter Phase II trial. J. Clin. Oncol. (2004) 22:2610-2616.
   PubMed Web of Science ®Google Scholar
• GRUNWALD V, HIDALGO M: Development of the epidermal growth factor receptor inhibitor OSI-774. Semin. Oncol. (2003) 30:23-31.
   PubMed Web of Science ®Google Scholar
• ROSETTI M, TESEI A, ULIVI P et al.: Modulation of drug cytotoxicity by Iressa (ZD1839) in pancreatic cancer cell lines. Cancer Biol. Ther. (2005) 4:1089-1095.
   PubMed Web of Science ®Google Scholar
• MOORE MJ, GOLDSTEIN D, HAMM J et al.: Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trial Group [NCIC-CTG]. Proc. Am. Soc. Clin. Oncol. (2005) 23:Abstract 1a.
   PubMed Web of Science ®Google Scholar
• SEQUIST LV, BELL DW, LYNCH TJ et al.: Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J. Clin. Oncol. (2007) 25:587-595.
   PubMed Web of Science ®Google Scholar
• KWAK EL, JANKOWSKI J, THAYER SP et al.: Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin. Cancer Res. (2006) 12:4283-4287.
   PubMed Web of Science ®Google Scholar
• YAMANAKA Y, FRIESS H, KOBRIN MS et al.: Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum. Pathol. (1993) 24:1127-1134.
   PubMed Web of Science ®Google Scholar
• SAFRAN H, IANNITTI D, RAMANATHAN R et al.: Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest. (2004) 22:706-712.
   PubMed Web of Science ®Google Scholar
• JOHNSTON SR, LEARY A: Lapatinib: a novel EGFR/Her2 tyrosine kinase inhibitor for cancer. Drugs Today (2006) 42:441-453.
   PubMed Web of Science ®Google Scholar
• BAKER CH, SOLORZANO CC, FIDLER IJ: Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res. (2002) 62:1996-2003.
   PubMed Web of Science ®Google Scholar
• SEO Y, BABA H, FUKUDA T et al.: High expression of vascular endotelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer (2000) 88:2239-2245.
   PubMed Web of Science ®Google Scholar
• DE GRAMONT A, VAN CUTSEM E: Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer. Oncology (2005) 69:46-56.
   Google Scholar
• KINDLER HL, NIEDZWIECKI D, HOLLIS E et al.: A double-blind, placebo-controlled, randomized phase III trial of gemcitabine plus bevacizumab versus gemcitabine plus placebo in patients with advanced pancreatic cancer: a preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303. ASCO GI (Orlando) (2007) :Abstract 108.
   Google Scholar
• CRANE CH, ELLIS LM, ABBRUZZESE JL et al.: Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J. Clin. Oncol. (2006) 24:1145-1151.
   PubMed Web of Science ®Google Scholar
• YOKOI K, SASAKI T, BUCANA CD et al.: Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. Cancer Res. (2005) 65:10371-10380.
   PubMed Web of Science ®Google Scholar
• MOLINA MA, SITJA-ARNAU M, LEMOINE MG et al.: Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroid anti-inflammatory drugs. Cancer Res. (1999) 59:4356-4362.
   PubMed Web of Science ®Google Scholar
• EL-RAYES BF, ZALUPSKI MM, SHIELDS AF et al.: A Phase II study of celecoxib, gemcitabine and cisplatin in advanced pancreatic cancer. Invest. New Drugs (2005) 23:583-590.
   PubMed Web of Science ®Google Scholar
• XIANG HQ, HESS KR, KAYALEH OR et al.: A phase II trial of gemcitabine and celecoxib for metastatic pancreatic cancer. Proc. ASCO J. Clin. Oncol. (2005) 23(Part I):165 Abstract 4174.
   Google Scholar
• ZALATNAI A: Molecular aspects of stromal – parenchymal interactions in malignant neoplasms. Cur. Mol. Med. (2006) 6:685-693.
   PubMed Web of Science ®Google Scholar
• BRAMHALL SR, SCHULZ J, NEMUNAITIS J et al.: A double-blind placebo-controlled, randomized study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br. J. Cancer (2002) 87:161-167.
   PubMed Web of Science ®Google Scholar
• JASNER R: Molecular regulation of pancreatic stellate cell function. Mol. Cancer (2004) 3:1-8.
   PubMed Web of Science ®Google Scholar
• SMORENBURG SM, VAN NOORDEN CJF: The complex effects of heparine on cancer progress and metastasis in experimental studies. Pharm. Rev. (2001) 1:93-106.
   Google Scholar
• LUDWIGR J, ALBAN S, BISTRIAN R et al.: The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo. Thromb. Haemost. (2006) 95(3):535-540.
   PubMed Web of Science ®Google Scholar
• KLERK CP, SMORENBURG SM, OTTEN HM et al.: The effect of low molecular weight heparin on survival in patients with advanced malignancy. J. Clin. Oncol. (2005) 23:2130-2135.
   PubMed Web of Science ®Google Scholar
• PELZER U, HILBIG A, STIELER J et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin chemotherapy (PROSPECT-CONKO 004). Proc. ASCO J. Clin. Oncol. (2006) 24(Part I):185 Abstract 4110.
   Google Scholar
• VAN CUTSEM E, VANDE VELDE H, KARASEH P et al.: Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol. (2004) 22:1430-1438.
   PubMed Web of Science ®Google Scholar
• LIEVRE A, BACHET JB, LE CORRE D et al.: KRAS mutations status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. (2006) 66:3992-3995.
   PubMed Web of Science ®Google Scholar
• VIVANCO I, SAWYERS CL: The phosphatidyl inositol 3 kinase AKT pathway in human cancer. Nat. Rev. Cancer (2002) 2:489-501.
   PubMed Web of Science ®Google Scholar
• DANCEY JE: Therapeutic targets: mTOR and related pathways. Cancer Biol. Ther. (2006) 5:1065-1073.
   PubMed Web of Science ®Google Scholar
• HOSSHINO R, CHATANI Y, YAMORI T et al.: Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene (1999) 18:813-822.
   PubMed Web of Science ®Google Scholar
• LORUSSO PM, ADJEI AA, VARTERASIAN M et al.: Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J. Clin. Oncol. (2005) 23:5281-5293.
   PubMed Web of Science ®Google Scholar
• CHOI M, WANG S, BANERJEE S et al.: Bcl-2 and Bcl-xL targeted therapy inhibits growth of pancreatic cancer cells. Gastrointestinal Cancers Symposium (2006): Abstract 143.
   Google Scholar
• KARIN M: Nuclear factor-kappa B in cancer development and progression. Nature (2006) 441:431-436.
   PubMed Web of Science ®Google Scholar
• LI L, AGGARWAL BB, SHISHODIA S et al.: Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their downregulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer (2004) 101:2351-2362.
   PubMed Web of Science ®Google Scholar
• LI L, BRAITEH FS, KURZROCK RL: Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signalling, and angiogenesis. Cancer (2005) 104:1322-1331.
   PubMed Web of Science ®Google Scholar
• ALBERTS SR, FOSTER NR, MORTO RF et al. PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study. Ann. Oncol. (2005) 16:1654-1661.
   PubMed Web of Science ®Google Scholar
• KEITH WN, BILSLAND A, EVANS TR et al.: Telomerase-directed molecular therapeutics. Expert Rev. Mol. Med. (2002) 20:1-25.
   Google Scholar
• GORDON JN, TREBBLE TM, ELLIS RD et al. Thalidomid in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut (2005) 54:540-545.
   PubMed Web of Science ®Google Scholar
• DEMETRI GD, VAN OOSTEROM AT, GARRETT CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet (2006) 368(9544):1329-1338.
   PubMed Web of Science ®Google Scholar
• DEEKS ED, KEATING GM: Sunitinib. Drugs (2006) 66(17):2255-2266.
   PubMed Web of Science ®Google Scholar
• ESCUDIER B, EISEN T, STADLER WM et al. Sorafenib in advanced clear-cell rena-cell carcinoma. N. Engl. J. Med. (2007) 356(2):185-187.
   PubMed Web of Science ®Google Scholar
• WALLACE JA, LOCKER G, NATTAM S et al.: Sorafenib plus gemcitabine for advanced pancreatic cancer: a Phase II trial of the University of Chicago Phase II consortium. ASCO GI (Orlando) (2007): Abstract 137.
   Google Scholar
• YOKOI K, THABER PH, YAZICI S et al. Dual inihibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model. Cancer Res. (2005) 65:3716-3725.
   PubMed Web of Science ®Google Scholar
• LI C, HEIDT DG, DALERBA P et al.: Identification of pancreatic cancer stem cells. Cancer Res (2007) 67(3):1030-1037.
   PubMed Web of Science ®Google Scholar
• HIDALGO M, RUBIO-VIQUEIRA B, WEEKES C et al.: In vivo platform for translational drug development and biomarker discovery in pancreatic cancer. Proc. ASCO J. Clin. Oncol. (2006) 24(Part I) 185 Abstract 4000.
   Google Scholar